Enzon appoints Dr. Jeffrey McGuire vice president, Research and Development and Chief Scientific Officer.PISCATAWAY, N.J.--(BUSINESS WIRE)--January 22, 1997--Enzon, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ENZN) announced today the appointment of Dr. Jeffrey McGuire to the newly created position of vice president, research and development and chief scientific officer. Dr. McGuire will be responsible for the research and clinical functions of the Company. This position was created to better enable the Company to direct its expanding array of research and clinical projects. Dr. McGuire holds a B.S. in Life Sciences from the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, and a Ph.D. in Life Sciences, with a concentration in molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller , from the University of Delaware [3] The student body at the University of Delaware is largely an undergraduate population. Delaware students have a great deal of access to work and internship opportunities. . Dr. McGuire served as a research scientist at the Frederick Cancer Research Center studying anthracycline anti-cancer compounds. Additionally, he conducted post-doctoral research at Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. . Dr. McGuire was with the Genex Corporation from 1980 until it was acquired by Enzon in 1991, where he held various research, business development and management positions. Since 1991, Dr. McGuire has been responsible for Enzon's Single-Chain Antigen-Binding (SCA (Single Connector Attachment) An 80-pin plug and socket used to connect peripherals. With a SCSI drive, it rolls three cables (power, data channel and ID configuration) into one connector for fast installation and removal. (R) protein licensing program and intellectual property portfolio. In addition, he has served as liaison between Enzon's R&D and business development activities. "Dr. McGuire possesses the scientific and management skills required for this important position," stated Peter G. Tombros, president and chief executive officer. "I am confident, that under Dr. McGuire's leadership, we will be able to expand our technologies, increase our strategic alliances and maximize our scientific and clinical efforts." Dr. Robert Shorr will assume the position of vice president, science and technology, reporting to Dr. McGuire. Dr. Shorr will be responsible for identifying new applications for Enzon's proprietary technologies and evaluating external technologies for potential licensing. Enzon is a biopharmaceutical company developing advanced therapeutics for life-threatening diseases through the application of its proprietary technologies. The Company's research activities are focused primarily in the area of oncology, including the development of a hemoglobin-based oxygen carrier as an enhancement to radiation therapy of solid tumors. Enzon has two FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved products -- ADAGEN(R), a treatment for Severe Combined Immunodeficiency Disease Noun 1. severe combined immunodeficiency disease - a congenital disease affecting T cells that can result from a mutation in any one of several different genes; children with it are susceptible to infectious disease; if untreated it is lethal within the first year or and ONCASPAR(R), for the treatment of acute lymphoblastic leukemia acute lymphoblastic leukemia n. Abbr. ALL Lymphoblastic leukemia occurring mainly in older adults, characterized by rapid onset and progression of symptoms. Also called acute lymphocytic leukemia. , which is being marketed by Rhone-Poulenc Rorer Pharmaceuticals, Inc. in North America and Medac GmbH in Europe. The Company also pursues commercialization of its proprietary technologies through strategic partnering including arrangements with Schering Corporation, Bristol-Myers Squibb Company, Baxter Healthcare Corporation and Eli Lilly & Co. Enzon is headquartered in Piscataway, NJ. CONTACT: Kimberly Cooper Enzon, Inc. Corporate Communications (908) 980-4577 http://www.enzon.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion